Table 2 Univariable and multivariable logistic regression analysis of factors associated with TMP-SMX use (N = 1877)

Age (years)

0.99

0.98–0.99

0.99

0.98–0.99

Female sex

0.61

0.49–0.76

0.63

0.50–0.80

Rituximab induction (vs maintenance)

1.46

1.14–1.87

1.24

0.95–1.62

Commercial/Medicare (vs Medicaid)

1.28

0.92–1.84

1.28

0.88–1.88

Year of index rituximab > 2015 (vs 2011–2015)

1.26

1.01–1.57

1.22

0.96–1.54

Hospital admission without intensive care (vs no hospitalization)^a

1.99

1.54–2.57

1.56

1.16–2.09

≥ 1 intensive care unit admission (vs no hospitalization)^a

2.28

1.72–3.02

1.95

1.39–2.73

Serious infection^a

1.53

1.06–2.18

0.89

0.59–1.34

Co-morbidity^b

0.96

0.77–1.19

0.91

0.71–1.17

Prednisone 1–19 mg/day (vs none)^c

2.86

2.00–4.06

2.63

1.83–3.77

Prednisone ≥ 20 mg/day (vs none)^c

4.92

3.84–6.33

3.96

3.04–5.19

Azathioprine^a

0.94

0.55–1.54

–

–

Methotrexate^a

1.55

1.12–2.13

1.48

1.04–2.09

Cyclophosphamide^a

1.02

0.53–1.81

–

–